US 12,433,867 B2
Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
In Hwan Bae, Hwaseong-si (KR); Ji Sook Kim, Hwaseong-si (KR); Jae Yul Choi, Hwaseong-si (KR); and Young Gil Ahn, Hwaseong-si (KR)
Assigned to Hanmi Pharm. Co., Ltd., Hwaseong-si (KR)
Appl. No. 17/432,699
Filed by HANMI PHARM. CO., LTD, Hwaseong-si (KR)
PCT Filed Feb. 21, 2020, PCT No. PCT/KR2020/002536
§ 371(c)(1), (2) Date Aug. 20, 2021,
PCT Pub. No. WO2020/171646, PCT Pub. Date Aug. 27, 2020.
Claims priority of application No. 10-2019-0021228 (KR), filed on Feb. 22, 2019; and application No. 10-2020-0021502 (KR), filed on Feb. 21, 2020.
Prior Publication US 2022/0110913 A1, Apr. 14, 2022
Int. Cl. A61K 31/404 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/404 (2013.01) [A61P 35/02 (2018.01)] 11 Claims
OG exemplary drawing
 
1. A method of treating acute myeloid leukemia (AML) in a subject in need thereof, wherein the method comprises administering to the subject an Fms-like tyrosine kinase-3 (FLT3) inhibitor or a pharmaceutically acceptable salt or solvate thereof,
in combination with an hypomethylating agent (HMA) or a pharmaceutically acceptable salt or solvate thereof,
wherein the FLT3 inhibitor is 5-chloro-N-(3-cyclopropyl-5-(((3R, 5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine having a structure

OG Complex Work Unit Chemistry